AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) Director Kathy Johnson Weiler sold 14,150 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AxoGen Trading Up 0.5%
NASDAQ AXGN traded up $0.26 on Tuesday, reaching $48.48. The stock had a trading volume of 576,927 shares, compared to its average volume of 1,114,968. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -71.29 and a beta of 1.11. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. AxoGen, Inc. has a 12-month low of $13.64 and a 12-month high of $49.12. The stock has a fifty day moving average price of $42.83 and a two-hundred day moving average price of $38.03.
AxoGen (NASDAQ:AXGN – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, hitting the consensus estimate of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The business had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. As a group, sell-side analysts forecast that AxoGen, Inc. will post -0.45 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on AxoGen
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Edmond DE Rothschild Holding S.A. purchased a new stake in AxoGen during the second quarter worth approximately $1,469,000. Lisanti Capital Growth LLC purchased a new stake in AxoGen in the second quarter valued at $4,183,000. Tocqueville Asset Management L.P. purchased a new position in shares of AxoGen during the second quarter worth about $8,032,000. BlackRock Inc. purchased a new position in shares of AxoGen during the second quarter worth about $204,123,000. Finally, Deutsche Bank AG purchased a new stake in shares of AxoGen in the 2nd quarter valued at about $30,106,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.
About AxoGen
AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.
The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.
Featured Stories
- Five stocks we like better than AxoGen
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
